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Abstract
The Core Binding Factor (CBF) protein RUNX1 is a master regulator of definitive hemato-
poiesis, crucial for hematopoietic stem cell (HSC) emergence during ontogeny. RUNX1
also plays vital roles in adult mice, in regulating the correct specification of numerous blood
lineages. Akin to the other mammalian Runx genes, Runx1 has two promoters P1 (distal)
and P2 (proximal) which generate distinct protein isoforms. The activities and specific rele-
vance of these two promoters in adult hematopoiesis remain to be fully elucidated. Utilizing
a dual reporter mouse model we demonstrate that the distal P1 promoter is broadly active in
adult hematopoietic stem and progenitor cell (HSPC) populations. By contrast the activity of
the proximal P2 promoter is more restricted and its upregulation, in both the immature Line-
age- Sca1high cKithigh (LSK) and bipotential Pre-Megakaryocytic/Erythroid Progenitor (Pre-
MegE) populations, coincides with a loss of erythroid (Ery) specification. Accordingly the
PreMegE population can be prospectively separated into “pro-erythroid” and “pro-megakar-
yocyte” populations based on Runx1 P2 activity. Comparative gene expression analyses
between Runx1 P2+ and P2- populations indicated that levels of CD34 expression could
substitute for P2 activity to distinguish these two cell populations in wild type (WT) bone
marrow (BM). Prospective isolation of these two populations will enable the further investi-
gation of molecular mechanisms involved in megakaryocytic/erythroid (Mk/Ery) cell fate
decisions. Having characterized the extensive activity of P1, we utilized a P1-GFP homozy-
gous mouse model to analyze the impact of the complete absence of Runx1 P1 expression
in adult mice and observed strong defects in the T cell lineage. Finally, we investigated how
the leukemic fusion protein AML1-ETO9amight influence Runx1 promoter usage. Short-
term AML1-ETO9a induction in BM resulted in preferential P2 upregulation, suggesting its
expression may be important to establish a pre-leukemic environment.
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Author Summary
The transcription factor RUNX1 is considered a master regulator of adult and embryonic
blood cell production. Mutations in RUNX1 cause defects in different blood lineages in
human patients and mouse models, including leukemia and blood clotting defects due to a
shortage of platelet-producing megakaryocytes. Together with the other RUNX genes pres-
ent in mammals, RUNX1 is expressed from two promoters, which produce several distinct
RNA transcripts and protein isoforms. To investigate the timing and localization of the
expression of these two promoters (termed distal and proximal), we created a mouse
model with reporter genes expressed under the control of the Runx1 promoters. We previ-
ously described the activities of the Runx1 promoters at the initiation of blood production
in the developing embryo. We now investigate the output from the two promoters in adult
organs, including bone marrow, spleen and thymus. We show here that the distal Runx1
promoter is highly expressed but the proximal promoter is more restricted and in particu-
lar marks the point in adult blood production where the red blood cell and megakaryocyte
pathways separate. The different proteins produced by these two Runx1 promoters may
therefore have different roles in driving the production of these two distinct cell types.
Introduction
Adult hematopoiesis is orchestrated by a series of lineage fate decisions that control the specifi-
cation of mature erythroid, myeloid and lymphoid blood cells from pluripotent HSCs. RUNX
transcription factors play key roles at different stages, activating or repressing transcriptional
targets through DNA binding in association with other lineage-specific and ubiquitous tran-
scription factors and cofactors [1,2]. RUNX1 (also known as Acute Myeloid Leukemia 1 or
AML1) is a master regulator of definitive hematopoiesis, broadly expressed in HSCs, progeni-
tors and mature populations, with the exception of terminally differentiated erythrocytes [3–
5]. RUNX1 activity is vital for the embryonic establishment of normal adult hematopoiesis
through the regulation of HSPC emergence in a process termed endothelial-to-hematopoietic
transition (EHT) [6–12]. Conditional deletion of Runx1 in adult mice, meanwhile, results in
hematological imbalances such as decrease of peripheral blood lymphocytes, expansion of
monocytes and granulocytes and impaired T cell maturation [13–15]. RUNX1 is also critical in
megakaryocytic maturation and platelet production [16,17]. The requirement for RUNX1 in
adult HSC maintenance is more controversial, with assertions of impaired long-term repopu-
lating ability in Runx1-null HSCs due to increased stem cell exhaustion being increasingly chal-
lenged [6,18,19].
The importance of normal CBF function extends to malignant hematopoiesis, with RUNX1
or CBFBmutations found in over 20% of acute myeloid and lymphoid leukemia cases [20].
Although impaired RUNX1 activity is frequently important for establishing a pre-leukemic
stage, WT RUNX1 protein is nonetheless necessary for maintaining AML1-ETO Acute Mye-
loid Leukemia (AML) [21,22]. Consequently, the investigation of RUNX1’s expression and
function in hematopoiesis is of considerable interest to developmental biologists and clinical
researchers alike.
All vertebrate Runx genes contain two alternative promoters, a distal P1 promoter and a
proximal P2 promoter thought to represent the initial “primitive” promoter [23–25]. The
major protein isoforms produced from the P1 and P2 promoters, RUNX1C and RUNX1B
respectively, differ in their N-terminal amino acid sequences; RUNX1C is 14 amino acids
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longer and begins with the MASDS sequence whereas RUNX1B begins with MRIPV, a feature
conserved in mice and humans [26,27]. P2 is the more active promoter at the onset of definitive
hematopoiesis in the E7.5 embryo [28,29]. P1 activity is subsequently upregulated, enriched in
definitive hematopoietic culture colony-forming unit (CFU-C) populations from E8.5 onwards
[29]. Analyses on whole cell populations revealed a remarkable switch to P1-dominant Runx1
expression at the fetal liver stage that is maintained in adult BM populations [28,29]. At this
stage P2 activity is only detected in some specific adult hematopoietic subsets. However, the
exact cell populations defined by the activities of P1 and P2 remain largely unknown.
To define the activities of the Runx1 promoters in adult HSPCs we utilized a previously
described distal-Green Fluorescent Protein (GFP), proximal-truncated human CD4 (hCD4)
(P1-GFP::P2-hCD4) dual reporter knock-in mouse line [29]. We observed that all Runx1‐posi-
tive adult BM populations expressed P1‐GFP, whereas P2‐hCD4 expression was highly
restricted. Phenotypic HSCs expressed solely P1‐GFP, with upregulation of P2‐hCD4 in CD48‐
positive multipotent progenitors (MPPs) coinciding with a significant downregulation of ery-
throid output. We also found that the PreMegE population could be prospectively separated
into P2‐hCD4‐ “pro‐erythroid” and P2‐hCD4+ “pro‐megakaryocyte” populations. Global gene
expression analyses identified various candidate cell surface markers which were differentially
expressed between the two PreMegE subpopulations. Among them, differential expression of
the hematopoietic cell antigen CD34 enabled the prospective isolation of CD34- “pro‐ery-
throid” and CD34+ “pro‐megakaryocyte” PreMegEs fromWT BM.
To further investigate the potential functional significance of the dominance of RUNX1C in
adult hematopoiesis, we investigated the impact of its absence in adult mice and found it to
recapitulate certain phenotypes observed in complete Runx1 knockout mouse models. We
observed perturbations in platelet versus erythroid output and altered splenic CD4 SP and
CD8 SP specification, suggesting certain lineages were more dependent on specific RUNX1C-
associated activity than others. Finally, we probed the potential specific RUNX1 isoform
requirements in AML by analyzing the impact of AML1-ETO oncogene expression on Runx1
promoter usage. Interestingly, AML1-ETO expression appeared to promote Runx1 P2 over P1
expression in several HSPC populations, suggesting that the Runx1 isoforms may have specific
functions both in normal and malignant hematopoiesis.
Results
Runx1 P1 is the dominant promoter in adult hematopoiesis
Utilizing the P1-GFP::P2-hCD4 reporter mouse model [29], we traced Runx1 expression for both
promoters in vivo at a single cell level in adult mice (with flow cytometry gates based on theWT
control tissues) (Fig 1A and 1B). We observed substantial heterogeneity of Runx1 expression within
adult BM; approximately 55% of all BM cells were P1-GFP positive, almost 21% co-expressing
P2-hCD4 (Fig 1B). Red blood cell lysis (using Ammonium-Chloride-Potassium (ACK) buffer) led
to the depletion of P1-GFP- P2-hCD4- cells; 97% of remaining cells expressed P1-GFP with 20% co-
expressing P2-hCD4. No P1-GFP- P2-hCD4+ cells were observed. In the spleen, approximately 70%
of cells expressed P1-GFP but only 1% co-expressed P2-hCD4, whereas in the thymus almost 100%
of cells expressed P1-GFP, a quarter of which also expressed P2-hCD4. Altogether these results
establish, in line with other reports, that P1 is the dominant Runx1 promoter in adult hematopoi-
etic populations and that the activity of P2 is much more restricted [28].
Taking advantage of our reporter model, we pursued a detailed examination of P1-GFP and
P2-hCD4 expression in mature lymphoid and erythro-myeloid populations (Figs 2 and S1).
Runx1 is expressed in definitive erythroid precursors, where it is involved in the regulation
of erythroid gene expression as part of a core transcription factor complex, but is subsequently
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downregulated in mature erythrocytes [3–5,28,30]. Correspondingly, P1-GFP expression was
restricted to 26% of the proerythroblast (CD71high Ter119int, ProE), 56% of the basophilic
erythroblast (CD71high Ter119high FSChigh, EryA) and 4% of the late basophilic/polychromatic
erythroblast (CD71high Ter119high FSClow, EryB) fractions whilst being completely absent in
the most mature CD71low Ter119high FSClow (orthochromatic erythroblasts, reticulocytes, red
blood cells, EryC) compartment (Figs 2A, 2B and S1A). P2-hCD4 was expressed in less than
1% of Ter119+ erythroid cells, being apparently entirely dispensable for adult erythropoiesis.
The low level of expression from both Runx1 P1 and P2 promoters, particularly the latter, in
WT erythroid lineage cells was confirmed at the RNA level by qPCR (S2A Fig).
By contrast to the restricted expression observed in the erythroid lineage, Runx1 P1-GFP
was expressed in almost 100% of mature myeloid CD11b+ BM cells (Figs 2C, 2D and S1B). Of
these, P2-hCD4 was co-expressed in 12% of Gr1high granulocytes, 39% of Gr1-/low monocytic/
immature granulocyte cells and 17% of F4/80+ macrophages. The decreased P2 activity in the
more mature granulocytic/macrophage (GM) fractions suggests a diminished role for
RUNX1B as myeloid differentiation progresses. This also appears to be the case for terminal
lymphoid differentiation, as P2-hCD4 co-expression with P1-GFP was restricted in the B-cell
lineage to 58% of the BM Pre-pro-B, almost half (49%) of the Pro-B and just 8% of the Pre-B
progenitors (Figs 2E–2H, S1C and S1D). P1-GFP was expressed in over 90% of BM B cell pro-
genitors but was reduced to approximately 80% of mature BM and spleen B cells. Finally,
Fig 1. Runx1 promoter P1 and P2 expression in adult hematopoietic organs. (A) Schematic diagrams of
the Runx1WT (top) and P1-GFP::P2-hCD4 dual reporter (GFP::hCD4, bottom) alleles. Expression of GFP is
directed by Runx1 promoter P1 and a truncated hCD4 reporter is expressed under the control of Runx1
promoter P2. (B) Contour plots of Runx1 P1-GFP and P2-hCD4 expression in unfractionated total (far left
panel) and ACK buffer lysed (middle left panel) adult BM, spleen (middle right panel) and thymus (far right
panel) inWT (top) and P1-GFP::P2-hCD4/+ (bottom) mice. Representative data of three independent
experiments are shown.
doi:10.1371/journal.pgen.1005814.g001
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thymic T cells were highly enriched in the P1-GFP+ P2-hCD4- fraction but P2-hCD4 activity
appeared to peak in the CD4 CD8 double negative 2 (DN2) fraction at approximately 61%
(Figs 2I, 2J and S1E). Interestingly, the more mature spleen CD4 and CD8 single positive (SP)
T cell subsets displayed greater heterogeneity than their thymic counterparts; almost 100% of
CD4 SP cells express P1-GFP whilst this is the case for only 20% of CD8 SP cells (Figs 2K, 2L
and S1F). Relative quantitation of the Runx1 isoforms’ expression revealed comparatively high
P1 and P2 activity in the GM, B and T lineages, peaking in the early thymic T cell CD4 CD8
DN population and provides direct evidence that the P1-GFP::P2-hCD4 reporters faithfully
representWT Runx1 expression throughout adult hematopoiesis (S2A–S2C Fig). Overall, P1
clearly dominates, accounting for over 80% of Runx1 expression in all analyzed lineage positive
populations. Nonetheless, strong P2 expression was observed in CD11b+ GR1+ GM cells, Pre-
pro/pro/pre-B cells and CD4 CD8 DN T cells, decreasing substantially in the more mature
IgM+ B and CD4/CD8+ T cells. These results indicate that P1 is the dominant Runx1 promoter
in terminally differentiated hematopoietic cells and suggest that downregulation of P2 is
required for maturation to occur. We therefore decided to determine whether P2 expression
has a greater prominence and significance in immature HSPC subsets.
Upregulation of Runx1 P2 in HSPCs marks a loss of erythroid potential
To examine the relative activities of the two Runx1 promoters in the most immature hemato-
poietic compartments, we separated the LSK fraction into phenotypic HSC and MPP fractions
(Fig 3A). We observed that only the P1 promoter was active in the HSCs and CD48- MPPs
(Fig 3C). The upregulation of CD48 expression coincides with the loss of long-term repopulat-
ing ability, the LSK CD48+ fraction consisting of a mixture of lymphoid and myeloid progeni-
tors with varying multipotentiality. FMS-Like Tyrosine Kinase 3 (FLT3) expression marks a
commitment to the GM and lymphoid lineages at the expense of Mk/Ery specification [31,32].
Increased GM/lymphoid lineage commitment appears to coincide with increased P2 activity,
as the majority of cells in the lymphoid-primed multipotent progenitor (LMPP)-enriched
FLT3+ and the common lymphoid progenitor (CLP, Fig 3B) subsets co-expressed P1-GFP and
P2-hCD4 (Fig 3C). Therefore, although P1 is the dominant Runx1 promoter at the onset of
adult hematopoiesis, our results suggest that P2 expression imparts or at least reflects distinct
lineage commitment decisions in these immature hematopoietic compartments. Consistent
with this theory, Runx1 P1 activity, as measured by quantitative RT PCR in WT BMHSPCs,
peaked in the WT HSCs and decreased by approximately 50% in the FLT3+ MPPs, coinciding
with the substantial increase in Runx1 P2 expression (S3 Fig). The overall result is that total
Runx1 expression decreases only modestly in MPPs compared to HSCs but the relative contri-
bution by P1 compared to P2 decreases substantially.
When the differences in biological potential were directly assessed in FLT3+ MPPs,
P2-hCD4- and P2-hCD4+ subpopulations were capable of relatively similar levels of lymphoid
and myeloid differentiation (Fig 3D and 3E bottom), although the increased GM:M CFU-C
ratio in the P2-hCD4- subset may suggest it represents a more immature population than its
P2-hCD4+ counterpart. However, the difference in lineage output by the FLT3- subsets was
more marked; P2-hCD4- LSK CD48+ FLT3- (LSK48F-) MPPs appeared to have reduced T cell
output (Fig 3D top) but enhanced multilineage myeloid colony-forming unit potential at the
Fig 2. Runx1 P1 and P2 expression in mature hematopoietic lineages. (A, C, E, G, I, K) Contour plots of Runx1 P1-GFP and P2-hCD4 expression in BM
erythroid (A), granulocytic/macrophage (C) and B lymphocyte populations (E), spleen B (G) or T (K) lymphocytes and thymocytes (I), as defined in S1 Fig. (B,
D, F, H, J, L) Numbers of Runx1 P1- P2-, P1+ P2- and P1+ P2+ cells as a proportion of defined BM erythroid (B), granulocytic/macrophage (D) and B
lymphocyte populations (F), spleen B (H) or T (L) lymphocytes and thymocytes (J). Representative data of three independent experiments are shown.
doi:10.1371/journal.pgen.1005814.g002
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expense of CFU-M output (Fig 3E and 3F). Co-culturing the LSK48F- progenitors with the
OP9 murine stromal cell line in myeloid differentiation media revealed that CD11b+/Gr1+ GM
output was significantly decreased and CD41+ megakaryocytic (Mk) cell production was
slightly increased in the P2-hCD4- fraction as a proportion of total cells (Fig 3G and 3H). As a
proportion of non-GM (CD11b-) cells, CD41+ Mk cell output was in fact significantly
increased in the P2-hCD4+ LSK48F- fraction. Most strikingly, Ter119+ erythroid cell output
was almost entirely restricted to the P2-hCD4- fraction. Our phenotypic characterization of
BM HSPCs therefore demonstrate that upregulation of Runx1 P2 not only occurs after loss of
HSC activity but also coincides with a substantial decrease in erythroid specification.
To determine whether LSK48F- P2-hCD4- and P2-hCD4+ progenitors arise sequentially or
independently in the hematopoietic hierarchy, sorted cells were cultured with pro-myeloid
cytokines for up to 18 hours and immunophenotypically characterized (S4A and S4B Fig).
Whereas the P2-hCD4+ fraction solely produced P2-hCD4+ LSK cells, P2-hCD4- cultures
yielded P2-hCD4- and P2-hCD4+ LSK cells (S4B Fig). In addition, LSK48F- P2-hCD4- cultures
produced more phenotypic erythroid (pre-erythroid colony-forming unit, PreCFUe or ery-
throid colony-forming unit, CFUe) or bi-potential PreMegE progenitors and fewer GM (Pre-
Granulocyte-Macrophage progenitor, PreGM or Granulocyte-Macrophage Progenitor, GMP)
and megakaryocyte progenitor (MkP) cells compared to LSK48F- P2-hCD4+ cells. Altogether
these data demonstrate a hierarchical relationship between an erythroid-biased P2-hCD4-MPP
population and increasingly pro-GM/Mk P2-hCD4+ progeny.
Runx1 P2 expression in GM-restricted progenitors enriches for
monocyte/macrophage specification
Although Runx1 P2 expression appears to decrease as GMmaturation proceeds, its expression
in the earliest identified GM-restricted progenitors remained unknown. We found that approx-
imately 80% of PreGMs and 70% of GMPs co-express P1-GFP and P2-hCD4 (Fig 4A and 4B).
Moreover, we found P2 expression (as determined by qRT-PCR) to be higher in the PreGM
and GMP than other analyzed WT BMHSPC populations but P1 expression was only 50%
and 25% of the level observed in HSCs (S3 Fig). High P2 activity therefore appeared to be
important for GM lineage commitment and we decided to investigate the functionality of the
P2-hCD4+ and minority P2-hCD4- GM progenitor populations. Interestingly, CFU-C activity
was significantly higher in the P2-hCD4+ fractions, compared to the P2-hCD4- populations, of
both PreGM and GMP populations, reflecting higher CFU-M and CFU-GM frequencies (Fig
4C–4E). In particular, the P2-hCD4- GMP fraction appeared to consist of monopotent granulo-
cytic and monocytic/macrophage progenitors rather than bipotential GM progenitors. Liquid
culture of the progenitors confirms an apparent bias against macrophage specification as F4/
80+ cell numbers were significantly diminished in P2-hCD4- PreGM and GMP cultures,
whereas Gr1high granulocyte output was unaltered (S5A and S5B Fig). Interestingly, production
of CD11b- cKit+ FcεR1α+ mast cells was also elevated in P2-hCD4- cultures and more detailed
analyses confirmed the absence of P2-hCD4 expression in immunophenotypic mast cell
Fig 3. Upregulation ofRunx1 P2 in HSPCsmarks a loss of erythroid potential. (A–B) Contour plots showing immature adult BM Lineage (Lin) negative
hematopoietic progenitors. (A) The LSK fraction can be separated into distinct HSCs, CD48- MPPs and more mature CD48+ MPPs on the basis of CD150,
CD48 and FLT3 expression. (B) The CLP is characterized as Lin- CD127+ cKitlow Sca1low. (C) Representative FACS plots of P1-GFP/P2-hCD4 expression in
HSCs, CD48- MPPs, CD48+ FLT3- (LSK48F-) MPPs, CD48+ FLT3+ (LSK48F+) MPPs and CLPs. (D) Numbers of B220+ CD19+ B cells and CD4+ CD8+ DP T
cells produced following co-culture ofWT, P1+ P2- and P1+ P2+ LSK48F- MPPs (top) and LSK48F+ MPPs (bottom) with OP9 (B cells) or OP9-DL1 (T cells) for
21 days. (n = 4). (E) CFU-C activity ofWT, P1+ P2- and P1+ P2+ LSK48F- MPPs (top) and LSK48F+ MPPs (bottom) following culture in pro-myeloid semi-solid
methylcellulose-based medium. (LSK48F-, n = 7; LSK48F+, n = 6.) (F) Photographs of representative LSK48F- derived methylcellulose colonies. (G)
Representative CD11b/Gr1, CD41 and Ter119 FACS plots of OP9 co-cultured LSK48F- MPPs isolated on day 8. (H) Quantification of CD11b+ Gr1+
granulocyte/macrophage (GM) cells, CD41+ megakaryocytes and Ter119+ erythrocytes in the progenitor/OP9 co-culture assays (n = 5).
doi:10.1371/journal.pgen.1005814.g003
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progenitors (MCp, S5A–S5C Fig). The decreased CFU-GM activity of the P2-hCD4- GM pro-
genitors implies that they reside later in the hematopoietic hierarchy than the P2-hCD4+ popu-
lations, but in vitro lineage tracing revealed that P2-hCD4- GMPs gave rise to P2-hCD4+ GMPs
(S5E Fig). P2-hCD4- PreGMs gave rise to P2-hCD4+ PreGMs and subsequently to P2-hCD4-
and P2-hCD4+ GMPs, the latter dominating (S5D Fig). Therefore even within the GM lineage,
differential Runx1 promoter activity appears to play a role in or at least correlate with crucial
cell fate decisions.
Distinct megakaryocytic and erythroid progenitors can be isolated on the
basis of Runx1 P2-hCD4 expression
Erythropoiesis and megakaryopoiesis are highly similar developmental pathways, sharing
numerous regulatory factors particularly at the point of lineage specification [33,34]. However,
Fig 4. Runx1 P2 expression in GM-restricted progenitors enriches for monocyte/macrophage
specification. (A) Contour plots of adult BM Lin- Sca1- cKit+ (LK) GM progenitors. The GMP and PreGM
progenitors can be distinguished on the basis of CD41, CD16/32, SLAMF1 (CD150) and Endoglin
expression. (B) Representative FACS plots of P1-GFP/P2-hCD4 expression in PreGM and GMP cells. (C–E)
CFU-C activity ofWT, P1+ P2- and P1+ P2+ PreGMs and GMPs following culture in pro-myeloid semi-solid
methylcellulose-based medium. (C) Total CFU-C numbers (%). (D-E) Granulocyte (CFU-G), macrophage
(CFU-M) and granulocyte/macrophage (CFU-GM) colony forming unit numbers per 100 plated PreGMs (D) or
500 plated GMPs (E). n = 4 independent experiments.
doi:10.1371/journal.pgen.1005814.g004
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there are key differences and the specificity of a megakaryocyte maturation defect in Runx1-
null adult BM implicates RUNX1 as a central player in Mk/Ery lineage determination [14].
Moreover, our observation that P2-hCD4- and P2-hCD4+MPPs have distinct Mk/Ery potential
led us to investigate Runx1 promoter activity in Mk/Ery-restricted progenitors further (Fig
5A). We observed that erythroid restricted PreCFUe and CFUe progenitors expressed solely
P1-GFP whereas the MkP was chiefly P1-GFP+ P2-hCD4+ (Fig 5B). Because mature megakar-
yocytes are scarce in adult mice, BM-derived megakaryocytes were obtained by culturing puri-
fied MkPs in vitro. CD41-expressing megakaryocytes expressed P2-hCD4 and a large fraction
(60%) co-expressed P1-GFP (Fig 5C). Whilst lineage-restricted megakaryocytic and erythroid
progenitors were highly homogeneous, the PreMegE fraction, which generates the MkP and
PreCFUe populations, was markedly more heterogeneous; approximately 75% express solely
P1-GFP whereas the remaining 25% were P1-GFP+ P2-hCD4+ (Fig 5B).
When compared to the relative homogeneity of the monopotent MkP, PreCFUe and CFUe
populations, the heterogeneity of the PreMegE led us to consider the possibility of two func-
tionally distinct and prospectively isolatable PreMegE subsets. We subsequently observed that
erythroid CFU-C activity (CFUes and erythroid blast-forming units (BFUes)) was significantly
enriched in the P2-hCD4- PreMegE fraction compared to the P2-hCD4+ population (Fig 5D
and 5E). By comparison, megakaryocyte CFU-C potential was highly enriched in the
P2-hCD4+ fraction (Fig 5D–5H). In the MkP population, the P2-hCD4+ fraction possessed
similar megakaryocytic CFU-C activity to its WT counterpart (S6A Fig), suggesting Runx1
haploinsufficiency did not significantly impair megakaryocyte colony formation. In addition to
being more numerous, CFU-Mks derived from P2-hCD4+ PreMegEs were also larger than
those derived from the P2-hCD4- fraction, the median number of cells per colony being dou-
bled (Fig 5E, 5G and 5H). To determine whether this was a result of increased proliferation in
the P2-hCD4+ PreMegE fraction, we analyzed their cell cycle status by measuring 5’ethynyl-2’-
deoxyuridine (EdU) incorporation and DNA content (S6B Fig). More P2-hCD4+ PreMegE
cells were in the EdU+ DNA Synthesis (S) phase compared to their P2-hCD4- counterparts,
suggesting P2-driven RUNX1B expression may confer a proliferative advantage on PreMegE
cells.
The distinct megakaryocytic and erythroid potential of the two PreMegE fractions was fur-
ther confirmed following co-culture with OP9 cells. After 7 days, P2-hCD4+ PreMegE cultures
contained significantly more CD41+ megakaryocytes and significantly fewer Ter119+ erythroid
cells than the P2-hCD4- PreMegE cultures (Fig 5I and 5J). In addition, we performed clonal
analyses by plating single P2-hCD4- and P2-hCD4+ PreMegEs with OP9 (S6C Fig). This dem-
onstrated that although the two fractions had similar clonal output (28% and 24% positive
wells respectively) the P2-hCD4+ fraction contained more bi-potent megakaryocytic/erythroid
progenitors (42.9% versus 25% “Mk + Ery”) and more monopotent megakaryocyte-producing
progenitors (31.4% versus 12.5% “Mk only”) than the P2-hCD4- fraction. The P2-hCD4- frac-
tion was highly enriched for monopotent erythroid-producing progenitors (62.5% “Ery only”
compared to 25.7% in the P2-hCD4+ co-cultures). Therefore, as in the immature LSK HSPC
compartment, upregulation of P2 expression in PreMegEs appeared to coincide with a loss of
erythroid and an enrichment of megakaryocytic specification.
To decipher their relative positions in the hematopoietic hierarchy, P2-hCD4- and
P2-hCD4+ PreMegE cells were cultured for up to 12 hours and analyzed (Fig 5K). We observed
that P2-hCD4+ PreMegEs made a more rapid transition to an MkP immunophenotype than
P2-hCD4- cells. In addition P2-hCD4- PreMegEs gave rise to both P2-hCD4- and P2-hCD4+
fractions in vitro, whereas the P2-hCD4+ fraction did not appear to downregulate P2-hCD4.
Taken together, these data suggest the P2-hCD4- PreMegE can be placed earlier in the hemato-
poietic hierarchy, giving rise to the P2-hCD4+ PreMegE. Interestingly, we also observed that
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cultured P2-hCD4+ LSK48F- cells produced only P2-hCD4+ immunophenotypic PreMegEs
(S4B Fig). The differences in megakaryocytic and erythroid lineage potential in the P2-hCD4
negative and positive LSK48F- fractions may therefore be due to the preferential downstream
specification of distinct PreMegE subpopulations.
Global gene expression analysis of Runx1 P2-hCD4 positive and
negative PreMegEs enables the identification of WT equivalents
To explore the distinct gene regulatory mechanisms involved in the bifurcation of the Mk/Ery
pathway, and to identify candidate genes which may serve as markers to isolate the progenitors
in WT BM, we performed global gene expression analysis by RNA-Seq (Fig 6A and S4 Table).
The expression patterns of WT, P2-hCD4+ (P2+) and P2-hCD4- (P2-) PreMegE samples were
clearly separated based on principal component analysis, with WT cells clustering between the
P2+ and P2- samples (S7A Fig). When directly comparing the P2+ and P2- populations, 4876
genes were found to be at least 2-fold differentially expressed (false discovery rate<0.05), 2681
being upregulated in P2+ and 2195 in P2- PreMegEs (Fig 6A and S4 Table). Gene Set Enrich-
ment Analyses (GSEA) revealed a significant correlation between P2-hCD4 expression and
activation of the Thrombopoietin (TPO) and Integrin pathways, both of which are crucial for
megakaryopoiesis (Figs 6B and S7B–S7D) [35–37]. In line with the observed increased prolifer-
ative capacity of P2-hCD4+ PreMegEs, cell cycle regulators were also enriched in this popula-
tion. Ingenuity pathway analysis (IPA) identified cell migration and blood cell recruitment as
highly enriched functions and integrin signaling as the most significant activated pathway in
P2-hCD4+ PreMegEs (S7E and S7G Fig). By contrast, functions and pathways associated with
cell death and cell cycle inhibition were highly enriched in P2-hCD4- PreMegEs (S7F and S7H
Fig).
To further validate the distinct “pro-megakaryocytic” and “pro-erythroid” phenotypes of
each PreMegE population, we screened, and validated by qPCR, the RNA Seq data for the
expression of known Mk/Ery regulators and markers (Fig 6C and 6D). Early erythroid-associ-
ated factors, including Kruppel-like factor 1 (Klf1) and the Erythropoietin receptor (Epor) were
significantly upregulated in P2-hCD4- PreMegEs whereas numerous megakaryocyte-specific
markers (Integrin alpha 2b (Itga2b or Cd41), Integrin beta 3 (Itgb3 or Cd61), Myeloproliferative
Leukemia Virus Oncogene (Mpl) and Platelet Factor 4 (Pf4)) were enriched in the P2-hCD4+
fraction. Interestingly, the transcription factors GATA binding protein 1 (Gata1) and Growth
Factor Independent 1B (Gfi1b) were upregulated in P2-hCD4- PreMegEs. Both factors are cru-
cial for the normal development of both megakaryocytic and erythroid lineages: deletion of
either Gata1 or Gfi1b results in an early block in erythropoiesis at the PreCFUe stage whereas
megakaryocytic maturation is impaired resulting in the accumulation of undifferentiated
megakaryoblasts [38–41]. It would therefore appear that high Gfi1b and/or Gata1 expression
promote erythroid specification whereas lower levels would favor megakaryocytic
Fig 5. Distinct megakaryocytic and erythroid progenitors can be isolated on the basis ofRunx1 P2-hCD4 expression. (A) Contour plots of adult BM
LKMk/Ery progenitors. The PreMegE, MkP, PreCFUe and CFUe populations can by distinguished on the basis of cKit, CD41, SLAMF1 (CD150), CD16/32
and Endoglin cell surface expression. (B) Representative FACS plots of P1-GFP/P2-hCD4 expression in PreMegE, MkP, PreCFUe and CFUe subsets.
(n = 8). (C) P1-GFP/P2-hCD4 expression in BMMkP-derived cultured CD41+ megakaryocytes. (n = 4). (D–H) CFU-C activity ofWT, P1+ P2- and P1+ P2+
PreMegEs. Cells were cultured either in pro-myeloid semi-solid methylcellulose-based medium (D) or in pro-megakaryocytic collagen-based MegaCultTM
medium (F). Photographs of representative PreMegE-derived methylcellulose (E) and MegaCultTM (G) colonies. (n = 5) (H) Numbers of megakaryocytes per
MegaCultTM CFU-Mk colony from 3 independent experiments (mean ± SD, Mann-Whitney U test). (I) Contour plots of OP9 co-cultured PreMegE cells
isolated on day 7 and stained with CD41 and Ter119 antibodies. (J) Quantification of CD41+ megakaryocytes and Ter119+ erythrocytes in the PreMegE/OP9
co-culture assays. (n = 5). (K) Representative FACS plots of PreMegE cells following short-term (12 hours) culture in pro-myeloid liquid medium. Top:
CD150/CD41 expression of LK CD16/32- progenitor cells. Middle: Endoglin/CD150 expression of LK CD41 negative CD16/32 negative progenitors. Bottom:
P1-GFP/P2-hCD4 expression of immunophenotypic PreMegE (LK CD41- CD16/32- Endoglin- CD150+) cells (n = 3).
doi:10.1371/journal.pgen.1005814.g005
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commitment, but ultimately an increase of both would be required for megakaryocytic matura-
tion and thrombopoiesis. It is therefore highly likely that differential expression of Gata1 and
Gfi1b at the PreMegE stage plays a role in Mk/Ery lineage determination and their differential
expression may be driven by P2-driven RUNX1B.
In order to distinguish “pro-megakaryocytic” and “pro-erythroid” PreMegE subsets in WT
mice by alternative means to our reporter line, we screened the list of differentially expressed
genes in P2-hCD4+ and P2-hCD4- PreMegEs for cell surface markers with commercially avail-
able antibodies validated for use in flow cytometry (S8A Fig). The majority of selected markers
had low RPKM values, with the exception of Itgb3 (Cd61) and Cd34 (Figs 6C–6E and S8B).
However, CD61 protein expression was not detected on P2-hCD4+ and P2-hCD4- PreMegE
cells by flow cytometry (S8C and S8D Fig). By contrast, CD34 expression was approximately
2-fold higher in P2-hCD4+ PreMegEs compared to P2-hCD4- cells, both in terms of numbers
of positive cells and median fluorescence intensity (MFI; Figs 6E and S8D). WT CD34+ and
CD34- PreMegEs were therefore FACS sorted to>95% purity (Fig 6E) and their lineage output
and Runx1 isoform expression elucidated. Importantly, Runx1 P2 expression was substantially
higher in the CD34+ PreMegEs compared to the CD34- fraction (S3 Fig). Interestingly, P1
activity was also increased in the CD34+ cells, resulting in a 20% increase in total Runx1 expres-
sion. It is therefore unclear how important expression of the RUNX1B isoform is for the pro-
motion of megakaryopoiesis compared to enhanced RUNX1 expression overall. Indeed, P2
transcripts were even more highly expressed in WTMkPs, contributing to the highest levels of
total Runx1 in all analyzed HSPCs (S3C Fig). However, P1 expression was in fact decreased in
MkPs compared to PreMegEs, offering additional evidence in favor of a specific pro-megakar-
yopoiesis role for the P2-specified RUNX1B protein.
Akin to P2-hCD4+ PreMegEs, WT CD34+ PreMegEs had enhanced CFU-Mk and dimin-
ished BFUe activity compared to CD34- cells (Fig 6F). Myeloid co-culture with OP9 stromal
cells confirmed these phenotypes, as CD34+ PreMegEs produced substantially more CD41+
megakaryocytes and fewer Ter119+ erythroid cells (Fig 6G and 6H). Single-cell OP9 co-culture
revealed the CD34+ PreMegE compartment was highly enriched for monopotent “Mk only”
progenitors (79.2% versus 41.7%) and bipotent “Mk + Ery” progenitors (20.8% versus 8.3%)
compared to the CD34- fraction (S8E Fig). By contrast, monopotent “Ery-only” progenitors
accounted for 50% of the CD34- PreMegE cultures but were apparently absent from the CD34+
fraction. We have therefore established the existence of prospectively isolatable “pro-megakar-
yocytic” CD34+ and “pro-erythroid” CD34- PreMegE cells in WT mice.
Deletion of the dominant RUNX1C isoform does not ablate adult
hematopoiesis but results in numerous lineage-specific defects
Having established that the P1-directed RUNX1C isoform is expressed throughout adult hema-
topoiesis, we decided to determine how its absence would impact the overall homeostasis of
the adult blood system. Previously, we utilized the P1-GFP homozygous mouse to investigate
the requirement for RUNX1C at the onset of hematopoiesis and found it to be dispensable for
Fig 6. Global gene expression analysis of Runx1 P2-hCD4+ and P2-hCD4- PreMegEs enables identification of WT equivalents. (A) Heat map
depiction of genes at least 2-fold differentially expressed between P1+ P2- (P2-) and P1+ P2+ (P2+) PreMegE samples, as determined by RNA Seq. Genes in
red are upregulated and genes in blue are downregulated. (B) GSEA showing significantly enriched signaling pathways in the gene set upregulated in P2+
PreMegEs relative to P2- PreMegEs. (C) Reads per kilobase per million mapped reads (RPKM) values of selected Mk/Ery- associated genes. (n = 3). (D)
Quantitative PCR (qPCR) validation of expression of genes depicted in D. (n = 5). (E) Representative FACS plots of CD34 expression in P2+ and P2-
PreMegEs (top) and unsorted, purified CD34+ and purified CD34- WT PreMegEs (bottom). (P1-GFP::P2-hCD4mice n = 3;WTmice n = 5). (F) CFU-C activity
of CD34+ and CD34- PreMegEs following culture in pro-myeloid semi-solid methylcellulose-based medium. (n = 5). (G) Contour plots of OP9 co-cultured
CD34+ and CD34- PreMegE cells isolated on day 7 and stained with CD41 and Ter119 antibodies. (H) Quantification of CD41+ megakaryocytes and Ter119+
erythrocytes in the PreMegE/OP9 co-culture assays (n = 4).
doi:10.1371/journal.pgen.1005814.g006
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hematopoietic commitment [29]. However, this may be due to P2 being the dominant pro-
moter at this stage. We therefore analyzed hematopoietic populations in adult WT, RUNX1C
heterozygous (P1-GFP/+) and homozygous knockout (P1-GFP/GFP) mice (Fig 7A). Despite
the high expression of P1 in erythroid, myeloid and lymphoid progenitors, we observed no sig-
nificant perturbation of circulating red or white blood cell numbers upon performing auto-
mated cell counts (Fig 7B). Erythroid differentiation appeared to be normal, as peripheral
blood hematocrit, hemoglobin concentration and the reticulocyte counts of the RUNX1C null
mice were unaltered compared to their WT and heterozygous littermates (S9A–S9C Fig). Simi-
larly, myelo-lymphoid cell fate decisions did not appear to be significantly affected, as the pro-
portions of circulating monocytes, neutrophils and lymphocytes were unaffected (S9D-F).
However, a modest but significant decrease in platelet numbers was observed in RUNX1C null
mice compared to both the WT and heterozygous animals (Fig 7B). Their plateletcrit was also
slightly decreased (albeit not to a significant extent) but the mean platelet volume was unal-
tered (S9G and S9H Fig). This suggests that, unlike in the conditional total Runx1 null adult
mouse model, platelet maturation is not impaired but specification may be hampered.
FACS analysis of circulating blood cells and BM confirmed the presence of equal propor-
tions of CD11b+ Gr1+ GM lineage and B220+ CD19+ B lymphoid cells in WT, P1-GFP/+ and
P1-GFP/GFPmice (Figs 7C and S10). However, the numbers of CD3ε+ T cells were signifi-
cantly reduced, suggesting that the absence of RUNX1C partially impairs T cell specification.
We therefore analyzed the thymic T cell populations in greater detail and found that CD4/8
DN, DP and SP population numbers were not altered in P1-GFP/GFPmice (Fig 7F). However,
the ratio of CD4 SP:CD8 SP T cells in the spleen was severely perturbed, as P1-GFP/GFPmice
had considerably fewer CD4 SP and more CD8 SP T cells compared to WT littermates (Fig 7G
and 7H). This therefore suggests that RUNX1C is dispensable for the DN to DP transition,
observed to be blocked in total Runx1 deficient mice [13]. Nonetheless, the RUNX1C knockout
recapitulates the defect in CD4 SP and CD8 SP T cell specification observed in total Runx1+/-
mice, clearly demonstrating an important role for P1-driven RUNX1 activity in the T cell line-
age [4,42,43].
To determine whether the absence of P1-directed RUNX1C expression impacts adult col-
ony-forming HSPC populations, we performed myeloid CFU-C assays on unfractionated BM
fromWT, P1-GFP/+ and P1-GFP/GFPmice (Fig 7D). GM, MkE and multilineage GEMM col-
ony numbers were unaffected, but RUNX1C null BM cells produced significantly more ery-
throid CFUe colonies than either the WT or P1-GFP/+ cultures. FACS analysis of unlysed BM
revealed a significant expansion of the EryC population in the RUNX1C null mice, a stage
which coincides with almost complete silencing of both the Runx1 P1 and P2 promoters (Fig
7E). In combination with the observed mild thrombocytopenia, it appears that the absence of
RUNX1C may favor erythroid specification over megakaryopoiesis, a phenotype observed
recently in mouse and human HSPCs depleted for total RUNX1 [44]. Overall, P1-directed
RUNX1C activity may be dispensable for normal adult hematopoiesis but its absence nonethe-
less results in defects reminiscent of total RUNX1 deficiency.
Expression of the AML1-ETO9a oncogene preferentially induces Runx1
P2 expression
Increasingly it is becoming apparent that, in addition to a more classically defined tumor sup-
pressor role, WT RUNX1 is required for the promotion of leukemogenesis in certain leukemia
subtypes. Notably, AML1-ETO-driven CBF AML appears to be dependent on maintaining
WT RUNX1 activity [21,22]. However, although AML1-ETO appears to promote RUNX1
expression, it is unclear whether AML1-ETO oncogene expression promotes the expression of
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one Runx1 promoter over another [45]. To address this question, we utilized a novel mouse
model expressing a Doxycycline-inducible AML1-ETO9a transgene under the control of a Tet-
racycline Responsive Element (TRE, Fig 8A). The AML1-ETO9a oncogenic transcript is
expressed in a majority of t(8;21) AML patients studied and encodes a truncated AML1-ETO
protein with enhanced leukemogenic potential [46,47]. We therefore took advantage of our
ability to induce AML1-ETO expression in adult mice (by administering Doxycycline in the
food for 8 days) and studied the impact on Runx1 isoform expression in vivo by isolating
AML1-ETO-expressing (AML1-ETO9a-IRES-GFP+) and non-expressing (AML1-ETO9a-
IRES-GFP-) BM HSPCs and quantitating Runx1 expression through qRT-PCR (Fig 8A). This
allowed us to study the effect of AML1-ETO expression on WT Runx1 expression as one of the
earliest events at the initiation of leukemogenesis.
Firstly, we confirmed the presence and absence of AML1-ETO9a expression in BM GFP+
and GFP- HSPCs respectively (Fig 8B). We chose to analyze LSK, PreGM and GMP cells as the
immature HSPC and GM-lineage progenitors contain the leukemia propagating cell fraction in
numerous AML patient samples and in a previously described AML1-ETOmouse model
[48,49]. Whilst in the PreGM, and GMP Runx1 P1 expression was unperturbed by the expres-
sion of AML1-ETO, it was in fact decreased by approximately 40% in LSK GFP+ cells compared
to GFP- (Fig 8D). In all three HSPC populations, however, the presence of AML1-ETO resulted
in an upregulation of Runx1 P2 expression (Fig 8E), albeit not to a significant extent in PreGM
cells. This resulted in an increase in total Runx1 expression in the GMP fraction (Fig 8C) but
also a significant decrease in the P1:P2 ratio in all three populations, particularly in the LSK
compartment, a phenotype associated with enhanced CFU-C activity, particularly in the GM
lineage (Fig 8F).
Discussion
Our understanding of the hematopoietic hierarchy, and of the complexity of cell fate decisions
in this system, has been increasingly refined in recent years. For a long time, it was assumed
that the most mature shared ancestor for all myeloid populations was the Common Myeloid
Progenitor (CMP), until this population was subsequently dissected and shown to be a hetero-
geneous population containing the PreGM and PreMegE fractions [50,51]. Using the Runx1
P1-GFP::P2-hCD4 dual reporter mouse model, we have now similarly demonstrated further
heterogeneity in the PreMegE fraction, prospectively isolating “pro-erythroid” P2- and “pro-
megakaryocytic” P2+ fractions (Fig 9). Moreover, we have successfully identified their
equivalents in WT BM as being CD34- and CD34+ respectively. CD34, a cell-cell adhesion fac-
tor previously characterized as a direct RUNX1 transcriptional target [52] and expressed on
vascular-associated tissue and selected HSPCs, was previously used to distinguish the CMP
from the Megakaryocyte/Erythroid Progenitor (MEP) [50]. By in vitro cell tracing experiments,
we have determined that the P2+ PreMegE lies directly downstream of the P2- PreMegE,
Fig 7. Impact of the absence of P1-directedRunx1 expression on adult hematopoiesis. (A) Top: Schematic diagrams of the Runx1WT (top) and
P1-GFP (bottom) alleles. Expression of GFP is directed by Runx1 promoter P1 but expression of Runx1 from the P2 promoter remains intact. Bottom:
Schematic diagram of the experimental design for the investigation of the impact of Runx1 P1 deletion on adult hematopoiesis. Peripheral blood, BM, thymus
and spleen samples were collected from adult WT, P1-GFP heterozygous (P1-GFP/+) and homozygous (P1-GFP/GFP) adult mice. All samples were
analyzed for mature blood cell surface marker expression. In addition, blood samples were subjected to automated cell counts (Sysmex) and CFU-C assays
were performed on unfractionated BM. (B) Peripheral blood cell counts of WT, P1-GFP/+ and P1-GFP/GFPmice as determined by Sysmex automated cell
counting. (C) Numbers of CD3e+ T cells, CD11b+ Gr1+ GM cells and B220+ CD19+ B cells as a proportion of total ACK-lysed blood cells fromWT,
P1-GFP/+ and P1-GFP/GFPmice. (D) CFU-C activity of WT, P1-GFP/+ and P1-GFP/GFP unfractionated ACK-lysed BM following culture in pro-myeloid
semi-solid methylcellulose-based medium. (n = 4.) (E) Numbers of erythroid lineage (ProE, EryA, EryB and EryC) cells as a proportion of live unfractionated
BM cells. (F) Numbers of T cell lineage populations as a proportion of live unfractionated thymus cells. (G) Numbers of CD4 SP and CD8 SP T cells as a
proportion of live unfractionated spleen cells. (H) Ratio of splenic CD4 SP T cells to splenic CD8 SP T cells (n = 4).
doi:10.1371/journal.pgen.1005814.g007
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Fig 8. Effect of short-term induction of AML1-ETO9a expression on Runx1 expression in BM HSPCs. (A) Top: Schematic representation of the Rosa26
andHprt loci in the Doxycycline-inducible AML1-ETO9a GFPmouse model. The reverse tetracycline-controlled transcriptional activator (rtTA) is
Runx1 Isoform Expression in Adult Hematopoiesis
PLOS Genetics | DOI:10.1371/journal.pgen.1005814 January 25, 2016 18 / 30
apparently contradicting a CMP-based model as this involves downregulation of CD34 expres-
sion prior to Mk/Ery lineage commitment. Moreover, we have demonstrated immunophenotypic
P2- PreMegEs can be directly derived from P2- LSK48F- MPPs, lending weight to the argument
that progenitors lose Mk/Ery potential before separation of the GM and lymphoid pathways
[32]. In fact, our model goes further, proposing that erythroid potential is downregulated prior
even to megakaryocytic potential, either coinciding with or as a direct result of Runx1 P2
upregulation.
Interestingly, comparative analysis of transcription factor binding motifs by rVISTA [53–
56] in the vicinity of the P1 and P2 regions revealed the presence of conserved erythroid tran-
scription factor EKLF (KLF1) motifs in the P1 region but none surrounding P2 (S11A and
S11B Fig). By contrast, FLI1-binding motifs are present in both regions. This is interesting as
RUNX1 has recently been implicated in regulating the balance of EKLF and FLI1 activity,
which promote Ery and Mk output respectively [44]. In addition, EKLF and FLI1 may in fact
act upstream of RUNX1, for example with EKLF directly activating Runx1 P1 but not P2
expression, a state which is reinforced by the enhanced EKLF expression in P1+P2- pro-ery-
throid PreMegEs compared to P1+P2+ pro-megakaryocytic PreMegEs. Analysis of ChIP-Seq
data from the mouse ENCODE project [53,54,57,58] also reveal some interesting differences in
GATA1 and SCL (TAL1) binding to the P1 and P2 promoter regions in megakaryocytes and
erythroblasts (S11C Fig). GATA1 and TAL1 binding appear largely unchanged in the vicinity
of the P1 promoter in both cell types. By contrast, GATA1 binding is observed at P2 and
GATA1+TAL1 binding approximately 15kb upstream in erythroblasts but not megakaryo-
cytes. It is conceivable, therefore, that GATA1-mediated transcriptional repression of the P2
promoter occurs in the erythroid lineage, whereas the absence of a GATA1-containing com-
plex enables its derepression and recruitment of activating factors instead.
The high number of differentially expressed genes (>4000) in the P2- and P2+ PreMegEs
lends credence to the hypothesis that they are derived from distinct progenitor ancestors. Com-
mitment to megakaryocytic or erythroid lineages may even occur earlier, at the HSC level; the
P2- and P2+MPPs may themselves be derived from pro-erythroid and pro-megakaryocyte
HSCs respectively as previously described [59–61]. Regardless of this, the increased purifica-
tion of phenotypically distinct progenitors within the hematopoietic hierarchy afforded by our
model will enable the investigation of molecular mechanisms involved in cell fate decisions
with significantly greater precision. In fact the role of RUNX1 in lineage commitment was
recently expanded to include promotion of megakaryopoiesis over erythropoiesis through
repression of KLF1 [44]. Overexpression studies were performed solely using a RUNX1B con-
struct and knockdown was non-isoform specific, so it remained unclear how important the iso-
form specificity is to the process of megakaryocytic or erythroid lineage commitment. Our
investigation of the P1-GFP/GFPmodel suggests RUNX1C plays a specific role in these line-
ages, as its absence means circulating platelet numbers are decreased whereas BM CFUes and
EryCs are increased. However, we cannot discount the fact that this phenotype may be due to
an overall decrease in RUNX1 protein as opposed to the specific loss of RUNX1C and therefore
further studies utilizing either targeted mutagenesis of the two Runx1 promoters separately or
constitutively expressed under the control of the Rosa promoter. Upon binding to Doxycycline, the rtTA is capable of binding to and activating a tetracycline
responsive element (TRE) located in the ubiquitously expressedHprt locus, resulting in expression of the hemagglutinin (HA)-tagged AML1-ETO9a::
IRES-GFP construct also incorporated into this locus. Bottom: Schematic diagram of the experimental design to induce short-term expression of
AML1-ETO9a in adult mice by administering Doxycycline in food for 8 days. Bone marrow cells were the harvested and GFP+ and GFP- HSPC populations
were isolated by FACS sorting for RNA extraction and gene expression analysis. (B-E) Gene expression analysis by qPCR of AML1-ETO9a (B), total Runx1
(C), Runx1 P1 (D) and Runx1 P2 (E). (F) Ratio of Runx1 P1:P2 expression (n = 3).
doi:10.1371/journal.pgen.1005814.g008
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isoform-specific knockdown whilst not impacting the overall level of RUNX1 would be
required to explore this possibility.
As previously mentioned, P1 is the dominant promoter in adult hematopoiesis, being active
in all Runx1-expressing populations. P2 expression is far more heterogeneous, confined to
immature/progenitor subsets of the GM and lymphoid lineages and megakaryocytes. With the
exception of megakaryocytes, it appears that downregulation of P2 is a prerequisite of terminal
differentiation of these lineages. We also observed that, at least in myeloid lineages, P2-expres-
sion correlates with enhanced CFU-C activity and in the PreMegE specifically with increased
proliferation. Numerous cell cycle regulators are upregulated in P2+ PreMegEs, several of
which have previously been identified as putative RUNX1-targets. A unique feature of mega-
karyocytic differentiation is polyploidisation achieved through undergoing numerous abortive
cell cycles. Cell cycle activators are therefore highly expressed in these cells, as is Runx1 P2. It is
also of interest that P2 expression has previously been observed in newly emerging embryonic
HSC-containing hematopoietic clusters but not in the more quiescent BM HSC populations
Fig 9. Model of Runx1 P1 and P2 expression in adult megakaryocytic/erythroid lineages. Runx1 P1 (red) and P2 (blue) expression in adult
hematopoietic stem, progenitor and lineage positive cells, as determined using the P1-GFP::P2-hCD4 double knock-in mouse model.
doi:10.1371/journal.pgen.1005814.g009
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[28]. Despite their distinct roles in hematopoiesis, many parallels have been drawn between the
specification of HSCs and megakaryopoiesis [62]. HSCs and MkPs share similar cell surface
marker profiles and have numerous regulatory pathways in common [63,64]. These include
critical dependence on TPO signaling and hematopoietic transcription factors, including the
CBF complex, Ets and HOX-related genes, several of which are upregulated in P2+ PreMegEs
(S4 Table) [62,65]. Megakaryocytes appear to have more in common with embryonic than
adult HSCs, their production being characterized by CD41 expression and RUNX1-depen-
dency [7,66]. Our observations therefore suggest that expression of P2-driven RUNX1B may
actively promote cell cycling, with a role in expanding HSPC numbers and is then downregu-
lated to allow terminal differentiation of the B/T/GM and erythroid lineages. It would be of
interest to investigate to what extent RUNX1B, and also RUNX1C, indeed directly regulate dif-
ferent transcriptional targets and the mechanisms through which they may achieve this.
In addition to erythroid progenitors, mast cell progenitor specification did not appear to
require P2 expression. Intriguingly, both are lineages which do not appear to be adversely
affected by the absence of Runx1; complete ablation of Runx1 in adult mice has no impact on
peripheral red blood cell numbers, whereas mast cell development is normal in Runx1 P1-null
mice [14,67]. Whether this suggests Runx1 expression is entirely incidental in these lineages
will need to be investigated further.
The requirement for WT RUNX1 activity in AML has been extensively studied in recent
years. In AML1-ETO CBF AML in particular, a balance of AML1-ETO and RUNX1 expression
must be maintained to promote stem cell gene expression and repress differentiation-associ-
ated gene expression [68]. Moreover, it appears AML1-ETO may directly regulate Runx1
expression, as depletion of AML1-ETO leads to a decrease in RUNX1 levels in Kasumi1 cells
[45]. However, whether expression of P1 or P2 was favored in this context had not been investi-
gated. By utilizing an inducible AML1-ETO mouse model, we were able to establish that
AML1-ETO expression resulted in a specific upregulation of Runx1 P2. We have found P2
expression coincides with enhanced CFU activity and proliferation in HSPCs. Ben-Ami et al.
previously demonstrated RUNX1 enhances the viability of preleukemic AML1-ETO-express-
ing cells [21], therefore it may be that RUNX1B activity specifically enhances a preleukemic
phenotype in emerging CBF AML leukemia propagating cells. Interestingly, Trombly et al.
observed the recruitment of AML1-ETO to P1 and the +23 enhancer but not to P2 in Kasumi1
cells [45]. Therefore, the mechanism of AML1-ETO’s activation of P2 is of considerable inter-
est. AML1-ETO may directly activate P2, potentially via the +23 enhancer or it may instead
promote expression of other transcriptional activators which enhance P2 activity. Alterna-
tively, AML1-ETOmay directly repress P1, resulting in a compensatory upregulation of P2 by
a secondary mechanism. These possibilities will all need to be explored further.
Materials and Methods
Mice
P1-GFP::P2-hCD4 and P1-GFPmice have previously been described [29]. The AML1-ETO9a-
IRES-GFP/rtTAmice were generated as follows: HA-tagged AML1-ETO9a cDNAs (provided
by the Zhang laboratory [47]) were subcloned into a tet-ON vector in front of an IRES-GFP as
described [69]. Ainv18 ES cells [69] (which constitutively express the rtTA under the control of
the Rosa26 promoter) were then transfected with this tetracycline-inducible AML1-ETO9a
construct by electroporation and stably transfected clones were selected with G418 (0.5mg/ml,
Life Technologies) for 10–14 days. Chimeric mice were then generated by injecting AML1-E-
TO9a-IRES-GFP/rtTA ES cells into C57BL6J blastocysts. To induce AML1-ETO9a-IRES-GFP
expression, 12 week-old mice were fed irradiated diet supplemented with 545mg/kg
Runx1 Isoform Expression in Adult Hematopoiesis
PLOS Genetics | DOI:10.1371/journal.pgen.1005814 January 25, 2016 21 / 30
Doxycycline (ssniff Spezialdiäten GmbH) for 8 days prior to humane culling and tissue collec-
tion. All animal work was performed under regulations governed by UK Home Office Legisla-
tion under the Animals (Scientific Procedures) Act 1986. Details of animal husbandry and
tissue collection are listed in S1 File.
Flow cytometry analysis and cell sorting
Dead cells were excluded using either 0.5μg/ml 7-Aminoactinomycin D (7-AAD, eBioscience)
or 1μg/ml Hoechst 33258 (Life Technologies). Biotinylated antibody staining was detected by a
secondary incubation step with fluorochrome-conjugated Streptavidin. Prior to flow sorting of
HSPCs, bone marrow cells stained with biotinylated anti-lineage antibodies were lineage-
depleted using anti-biotin-conjugated magnetic beads (Miltenyi) and then stained with addi-
tional antibodies, including conjugated streptavidin. Red blood cell depletion was performed
by treatment with ACK lysis buffer (154mM ammonium chloride, 9.99mM potassium bicar-
bonate, 0.110mM EDTA) for 5 minutes at room temperature, followed by quenching with
Phosphate-Buffered Saline (PBS).
Details of flow cytometry antibodies and reagents are listed in S1 Table. Details of flow
cytometry antibody combinations used for each analysis or sort are listed in S2 Table.
For cell cycle analysis, in vivo EdU incorporation was performed by injecting 1.125mg EdU
dissolved in PBS intraperitoneally into adult mice. After two hours, bone marrow was har-
vested and stained with hematopoietic stem and progenitor cell surface markers as detailed in
S2 Table. Cells were then stained using the Click-iT EdU Alexa Fluor 647 Flow Cytometry
Assay Kit (Life Technologies). Total DNA was stained with 1μg/ml FxCycle Violet Stain (Life
Technologies).
Cells were analyzed using a LSR-II or LSR-II Fortessa analyzer, a FACSAria-II cell sorter or
a FACSAria-III cell sorter (BD).
Automated peripheral blood counts
Tail vein blood (no more than 50μl per mouse) was sampled from 12 week old mice using hep-
arinized end-to-end Micro Pipettes (Vitrex) and analyzed on a Sysmex XT 2000i analyzer,
according to the manufacturer’s instructions.
Cell culture
OP9 and OP9-DL1 co-culture. Cells were cultured in 5% CO2 and 5% O2 at 37°C. Mouse
OP9 stromal cells were maintained in Alpha-MEM (Lonza) supplemented with 10% fetal
bovine serum (FBS, Sigma-Aldrich), 2mM L-glutamine (Gibco), 1x Penicillin-Streptomycin
(Sigma-Aldrich) and were routinely tested for mycoplasma contamination. For myeloid OP9
co-culture PreMegE and LSK48F- MPPs were seeded on mouse OP9 stromal cells (approxi-
mately 5000/ml) at a density of approximately 2000 cells/ml in IMDM (Lonza) supplemented
with 10% Fetal Bovine Serum (FBS) for Mouse Myeloid Colony-Forming Cells (StemCell
Technologies), 0.45mMmonothioglycerol (MTG, Sigma-Aldrich), 2mM L-glutamine (Gibco),
1x Penicillin-Streptomycin (100U/ml Penicillin, 100μg/ml Streptomycin, Sigma-Aldrich), 2U/
ml erythropoietin (Eprex, Janssen-Cilag Ltd), and medium conditioned by cell lines producing
IL3, TPO and Stem Cell Factor (SCF) (1% final concentration). PreMegEs were cultured for 7
days and LSK48F- MPPs for 8 days before being harvested and stained for myeloid cell surface
markers (TER119, CD41, GR1 and CD11B as detailed in S2 Table). For single cell co-culture,
single PreMegE cells were directly sorted into 96-well plate wells containing 100μl of the above
medium and approximately 500 OP9 cells and cultured for 7 days before positive wells were
assessed by microscopy and FACS analyzed as above.
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For B cell and T cell co-culture LSK48F- MPPs were seeded on mouse OP9 and OP9-DL1
stromal cells respectively at a density of approximately 2000 cells/ml in IMDM supplemented
with 20% FBS (Harlan), 2mM L-glutamine, 1x Penicillin-Streptomycin, 5ng/ml FLT3L (Pepro-
Tech) and 1ng/ml IL7 (PeproTech). Cultures were passed into fresh media every 4–5 days for
21 days (with IL7 concentrations reduced to 0.25ng/ml in OP9-DL1 co-cultures from day 12
onwards) and harvested and stained for B and T cell surface markers (CD45R (B220), CD19,
CD4 and CD8A as detailed in S2 Table).
Short-term culture of HSPCs. Purified PreGM, GMP and PreMegE cells were cultured at
37°C in 5% CO2 and atmospheric O2 for 6–18 hours in pro-myeloid medium (IMDM supple-
mented with 10% FBS for Mouse Myeloid Colony-Forming Cells, 10% Protein-free hybridoma
medium (PFHM-II, Gibco), 180μg/ml Transferrin (Roche Diagnostics), 0.45mMMTG, 50ng/
ml ascorbic acid (Sigma-Aldrich), 2mM L-glutamine, 1x Penicillin-Streptomycin, 4U/ml eryth-
ropoietin, 5ng/ml IL11 (R&D Systems), 10ng/ml IL6 (R&D Systems), 10ng/ml M-CSF (R&D
Systems) and medium conditioned by cell lines producing IL3, GMCSF, TPO and SCF (1%
final concentration)). Purified LSK48F- MPPs were cultured for 12–24 hours in Alpha MEM
(Lonza) supplemented with 10% FBS, 0.45mMMTG, 2mM L-glutamine, 1x Penicillin-Strepto-
mycin, 1U/ml erythropoietin, and medium conditioned by cell lines producing IL3, TPO and
SCF (1% final concentration)) (adapted from [70]). Cells were then harvested and stained with
either LSK HSPC markers or myeloid progenitor markers as described in S2 Table.
For longer-term culture (7–11 days), PreGM and GMP cells were cultured in pro-myeloid
medium as described above before being harvested and stained with GM and mast lineage
markers (CD11B, GR1, F4/80, C-KIT and FCER1A as detailed in S2 Table).
Sorted MkP cells were cultured for 4 days in pro-myeloid medium (see above).
Hematopoietic colony-forming assays. Methylcellulose colony-forming assays were per-
formed as previously described [71], except 10% (FBS) (StemCell Technologies) was added in place
of the Fetal Bovine Plasma-derived Serum Platelet Poor (PDS). 200 PreMegEs or 50 LSK48F-
MPPs were plated per dish in duplicate. CFUes were scored after 3–4 days and other colonies after
8 days under a microscope (DM IL; Leica). Megakaryocyte-specific colony-forming assays were
performed by plating 1000MkPs or PreMegEs in MegaCultTMmedium (StemCell Technologies).
Cells were cultured, fixed, stained and analyzed according to the manufacturer’s protocols.
Gene expression
Quantitative PCR. RNA was extracted using the RNeasy Plus Micro Kit (QIAGEN).
Complementary DNA was synthesized using the SuperScript III First-Strand Synthesis System
(Life Technologies). Quantitative PCR (qPCR) was performed using Universal ProbeLibrary
assays (Roche); primers and probes are listed in S3 Table. With the exception of TER119+ ery-
throid and CD11b+ GR1+ GM lineage cells, expression values were normalized to beta-actin
(b-actin). Owing to the significant variation of b-actin in these lineages, total Runx1 expression
in these compartments was calculated relative to input and normalized to the level in CD11b
+ GR1+ cells. To determine the relative contributions of Runx1 P1 and P2 transcripts to total
Runx1 expression, the relative efficiencies of the qPCR primers were calculated in a titration
experiment using known quantities of P1 and P2-expressing plasmid template DNA.
RNA sequencing. Tissues from 3 mice were pooled per sample. Total RNA was extracted
from purified PreMegEs as described above. Indexed PolyA libraries were prepared using 50ng
of total RNA and 16 cycles of amplification in the Agilent SureSelect Strand-Specific RNA
Library Prep Kit for Illumina Sequencing (Agilent). Libraries were quantified by qPCR using a
KAPA Library Quantification Kit for Illumina platforms (Kapa Biosystems Inc.). Paired-end
75bp sequencing was carried out by clustering 1.7pM of the pooled libraries on a NextSeq 500
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sequencer (Illumina Inc.) for 3 biological replicates per population. Details of sequence data
analysis are given in S1 File.
The data discussed in this publication have been deposited in NCBI’s Gene Expression
Omnibus [72] and are accessible through GEO series accession number GSE68958.
Statistical analysis
Flow cytometry plots display the mean values of each indicated population. Unless otherwise
indicated, data were evaluated using an Ordinary 2-way ANOVA and expressed as
mean ± standard error of the mean (SEM). P<0.05 was considered statistically significant.
P<0.05, P<0.01, P<0.001, P<0.0001
Supporting Information
S1 Fig. Immunophenotypic characterization of BM, spleen and thymus hematopoietic line-
age positive populations. (Related to Fig 2) (A–F) Contour plots of lineage marker expression
in adult BM (A, B, C), spleen (D and F) and thymus (E). (A) CD71/Ter119 expression of live
cells (left) and CD71 expression/FSC of Ter119 high cells (right) in BM. (B) CD11b/Gr1 (left)
and CD11b/F4/80 (right) expression in live BM cells. (C) B220/CD11b+CD3ε+Ter119 expres-
sion in live cells (left), cKit/CD19 expression in B220+ cells (middle) and IgM/IgD expression
in B220+ CD19+ cKit- cells (right) in BM. (D) B220/CD19 expression in live cells (left) and
IgM/IgD expression in B220+ CD19+ cells (right) in spleen. (E) CD4/CD8a expression in live
cells (left) and CD25/CD44 expression in CD4 CD8 double negative (DN) cells (right) in thy-
mus. (F) CD4/CD8a expression in live spleen cells.
(PDF)
S2 Fig. Comparative Runx1 expression in WTmature lineage positive populations. (Related
to Fig 2) (A-C) Gene expression analysis of Runx1 P1 and Runx1 P2 as a proportion of total
Runx1 in erythroid and GM (A), B (B) and T (C) cell lineage populations isolated fromWT
BM, spleen and thymus. (n = 3.) Owing to the high variability in b-actin expression in mature
erythroid and GM blood cells, gene expression values for these populations were normalized to
input and expressed relative to CD11b+ Gr1+ cells. Otherwise gene expression is depicted rela-
tive to b-actin.
(PDF)
S3 Fig. Runx1 expression in WT BMHSPCs. (Related to Figs 3–6) (A-C) Gene expression
analysis of total Runx1 (A), Runx1 P1 (B) and Runx1 P2 (C) in Lin- cKit+ HSPC populations
isolated fromWT BM, normalized to b-actin (n = 3).
(PDF)
S4 Fig. In vitro tracing ofWT and P1-GFP::P2-hCD4/+ LSK48F- hematopoietic progeni-
tors. (Related to Fig 3) Representative FACS plots of LSK48F- MPPs following 18 hours in
vitromyeloid culture. (A) Lin, cKit/Sca1, CD150/CD41, CD16/32 and Endoglin/CD150
expression of WT, P2+ and P2- cultured LSK48F- cells. (B) P1-GFP/P2-hCD4 expression of
LSK48F- derived immunophenotypic LSK and PreMegE cells (n = 3).
(PDF)
S5 Fig. In vitro differentiation ofWT and P1-GFP::P2-hCD4/+ PreGM and GMP progeni-
tors. (Related to Fig 4) (A–B) Top: FACS plots of CD11b/F4/80 and cKit/FcεR1α expression of
day 11 cultured PreGM (A) and GMP (B) cells. Bottom: quantification of GM subsets following
7 and 11 days culture. (n = 4). (C) P1-GFP/P2-hCD4 expression in the BM Lin- cKit+ Sca1-
FcεR1α- CD27- Ly6c- Integrin Beta7+ MCp. (Representative of 3 independent experiments.)
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(D-E) Representative FACS plots of PreGMs (D) and GMPs (E) following 12 hours in vitro
myeloid culture. (D) CD16/32/CD150, Endoglin/CD150 and P1-GFP/P2-hCD4 expression of
PreGM-derived cells. (E) CD16/32/Cd150 and P1-GFP/P2-hCD4 of GMP-derived cells.
(n = 3)
(PDF)
S6 Fig. Cell cycle and clonal analysis ofWT and P1-GFP::P2-hCD4/+Mk/Ery Progenitors.
(Related to Fig 5) (A) CFU-C activity ofWT and P1+ P2+ MkPs following culture in Mega-
CultTM medium. (n = 5). (B) Cell cycle status ofWT, P1+ P2- and P1+ P2+ PreMegEs, as deter-
mined by in vivo EdU incorporation and DNA content analysis. (n = 3). (C) Table showing the
clonal analysis of P1+ P2- and P1+ P2+ PreMegEs. Shown are the numbers of positive wells at
day 7 of OP9 co-culture relative to the numbers of single PreMegE cells plated on day 0 and the
proportion of wells that contained CD41+ cells (Mk only), Ter119+ cells (Ery only) or CD41+
and Ter119+ cells (Mk + Ery). Data are compiled from 5 independent experiments.
(PDF)
S7 Fig. Global gene expression analysis of P2- and P2+ PreMegEs. (Related to Fig 6) (A)
Principal component analysis of the RNA Seq expression data fromWT, P2- and P2+ PreMegE
cells. (B-D) Heat maps depicting expression of gene sets from GSEA plots (displayed in Fig 6B)
in P2- and P2+ PreMegE cells. (E–F) Diseases/functions upregulated (E) or downregulated (F)
in P2+ PreMegEs compared to P2- PreMegEs as determined by IPA. (G–H) Signaling pathways
activated (G) or inhibited (H) in P2+ PreMegEs compared to P2- PreMegEs as determined by
IPA.
(PDF)
S8 Fig. Candidate P2+ PreMegE cell surface markers and clonal analysis of CD34+/- WT
PreMegEs. (Related to Fig 6) (A) Log fold change (counts) of cell surface markers in P2+ Pre-
MegEs compared to P2- PreMegEs as determined by RNA Seq. (B) RPKM values of cell surface
markers in WT, P2- and P2+ PreMegEs. (n = 3). (C) Representative FACS plot of CD61 expres-
sion in P2+ and P2- PreMegEs. (n = 2). (D) Ratio of median fluorescence intensity (MFI) and
percentage of positive cells for CD61 and CD34 protein expression in P2+ PreMegEs compares
to P2- PreMegEs, determined by FACS. (n = 2). (E) Table showing the clonal analysis of
CD34+ and CD34-WT PreMegEs. Shown are numbers of positive wells at day 7 of OP9 co-cul-
ture relative to the numbers of single PreMegE cells plated on day 0 and the proportion of wells
that contained CD41+ cells (Mk only), Ter119+ cells (Ery only) or CD41+ and Ter119+ cells
(Mk + Ery). Data are compiled from 3 independent experiments.
(PDF)
S9 Fig. Additional parameters derived from Sysmex analysis of peripheral blood from
Runx1 P1 null adult mice. (Related to Fig 7) (A-H) Quantitation of Hematocrit (A), Total
hemoglobin concentration (B), Reticulocyte count (C), Monocyte count (D), Neutrophil count
(E), Lymphocyte count (F), Plateletcrit (G) and Mean Platelet Volume (H) in peripheral blood
ofWT, P1-GFP/+ and P1-GFP/GFPmice. (n = 4)
(PDF)
S10 Fig. FACS analysis of mature GM and B cell lineage cells in Runx1 P1 null adult mice.
(Related to Fig 7) (A—B) Numbers of GM (A) and B (B) lineage cells as a proportion of live
ACK-lysed BM cells. (C) Numbers of B lineage cells as a proportion of live ACK-lysed spleen
cells (n = 4).
(PDF)
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S11 Fig. In silico analysis of potential Mk/Ery transcription factor binding motifs in the
Runx1 P1 and P2 promoter regions. (A-B) rVISTA analysis of EKLF, FLI1, GATA1 and
TAL1 binding motifs located in regions surrounding Runx1 P1 (A) and Runx1 P2 (B). Top,
Blue: All motifs found in the mouse loci. Top, Green: Motifs conserved between mouse and
human. Middle: Genetic conservation between mouse and human loci. Bottom: Schematic of
mouse Runx1 locus, aligned to conservation map. (C) UCSC Browser tracks of mouse Runx1
locus, featuring GATA1 and TAL1 ChIP-seq data (performed in megakaryocytes and erythro-
blasts) acquired by the Mouse ENCODE Project, aligned to UCSC Runx1 transcripts and verte-
brate genetic conservation data.
(PDF)
S1 Table. Details of flow cytometry reagents.
(DOCX)
S2 Table. Antibody combinations used for FACS analysis and sorting.
(DOCX)
S3 Table. Primers and probes used for qPCR.
(DOCX)
S4 Table. Differentially expressed genes in P2- and P2+ PreMegEs.
(XLSX)
S1 File. Supplemental methods and references.
(DOCX)
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